The emergence of modern cancer immunotherapy

Annals of Surgical Oncology

Volumn 12, Issue 5, 2005, Pages 344-346

  Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CANCER IMMUNOTHERAPY; CANCER RESEARCH; EDITORIAL;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; MELANOMA;

EID: 21144440906     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2005.01.904     Document Type: Editorial

References (13)

1. SA Rosenberg JC Yang DE White SM Steinberg 1998 Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response Ann Surg 228 307 19
2. US Kammula DE White SA Rosenberg 1998 Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer Cancer 83 797 805
3. Spanknebel K, Cheung KY, Stoutenburg J, et al. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2. Ann Surg Oncol (in press)
4. SA Rosenberg 2001 Progress in human tumour immunology and immunotherapy Nature 411 380 4
5. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 909 15
6. SA Rosenberg BS Packard PM Aebersold 1988 Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma Preliminary report. N Engl J Med 319 1676 80
7. ME Dudley JR Wunderlich PF Robbins 2002 Cancer regression and autoimmunity in patients following clonal repopulation with anti-tumor lymphocytes Science 298 850 4
8. ME Dudley JR Wunderlich JC Yang 2005 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2346 2357
9. GQ Phan JC Yang RM Sherry 2003 Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc Natl Acad Sci USA 100 8372 7
10. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 207 14
11. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 16
12. SA Rosenberg MT Lotze LM Muul 1985 Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer N Engl J Med 313 1485 92
13. MT Lotze AE Chang CA Seipp C Simpson JT Vetto SA Rosenberg 1986 High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment related morbidity and histologic findings JAMA 256 3117 24